CEO John Johnson has said he expects this year's (2013) Provenge sales to exceed the $325 million-Direct To Consumer DTC advertising working well for the company. Provenge shows that small market drugs can use DTC given high revenue per patient. It is not a given they will get their 225 new users but I would be optimistic that they will exceed that number. The ad is clear, hopeful, and uses what every guy responds to. That is, your family needs you to be around as long as possible.
I would also expect Provenge to have a platinum level system of consumer support. I would hope they have live operators available 24/7 to answer questions. I would expect them to Fedex information out if requested. For $90,000 they can afford to coddle interested consumers. As a male in the prostate cancer age group I hope to never need it but I am glad it is out there.
Blah Blah Blah, I know you are a pumper. How come you make no mention of JNJ sale for zytiga today? Well you want to talk facts or listen to a second rate ceo like Johnson who first commented when he took the position that zytiga was no competition for provenge, then finally admits that thing aren't good because of competition. What a DOPE!. Here you Go: 2nd qtr sales in US were 174M vs. 113M and a total of 395M WW. No this is not a typo, theses numbers are real so don't let go of that chair because I see a #$%$ poor qtr maybe the worst ever. ewait a couple of weeks to see if they revise their numbers lower. Good luck #$%$ pumper!
Community clinics account for 71% of sales, “which is where we believe the long term revenue potential exists,” said DePinto. “While adding new infusing accounts is important, our focus remains on penetrating our existing customer account base to increase our depth of sales, which drives volume.”